Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Novel device provides retina's neural code to restore normal vision

Two researchers at Weill Cornell Medical College have deciphered a mouse's retina's neural code and coupled this information to a novel prosthetic device to restore sight to blind mice.

15 Aug 2012

Physiotherapy beneficial for Parkinson’s patients

Results from a systematic review and meta-analysis published in the BMJ suggest that physiotherapy interventions benefit Parkinson’s disease patients, at least in the short term.

14 Aug 2012

Latrepiridine reduces level of at least two neurodegeneration-related proteins in mice

14 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Latrepirdine demonstrates new potential against neurodegenerative conditions

The second of two studies on latrepirdine, recently published in Molecular Psychiatry, demonstrates new potential for the compound in the treatment of Alzheimer's disease, Parkinson's disease, sleep disorders, and other neurodegenerative conditions. An international team led by Mount Sinai School of Medicine scientists found that latrepiridine, known commercially as Dimebon, reduced the level of at least two neurodegeneration-related proteins in mice.

13 Aug 2012

Johns Hopkins CIDR receives NIH contract to study genetic diseases

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

13 Aug 2012

Combination of novel drug therapy and PSA test can effectively detect prostate cancer

Researchers have successfully developed and tested a new prostate cancer screening method that uses the combined power of a novel drug therapy and changes in PSA levels over time to identify men with a high PSA who are more likely to have aggressive prostate cancer despite negative biopsies.

12 Aug 2012

Researchers develop and test new prostate cancer screening method

9 Aug 2012

Technology for assessing Bradykinesia response to novel therapies in Parkinson’s Disease to be developed by Great Lakes NeuroTechnologies

Great Lakes NeuroTechnologies announced today that they have received $1.5 million in funding to commercialize a technology for Parkinson’s disease (PD) patients that will better assess motor symptoms in response to new deep brain stimulation (DBS) and pharmaceutical therapies.

8 Aug 2012

Healthcare professionals receive SingHealth Duke-NUS Scientific Congress abstract awards

Results of the highly anticipated Best Oral Presentation and Best Poster Awards were announced at SingHealth Duke-NUS Scientific Congress 2012, held on 3 and 4 August 2012 at the Raffles City Convention Centre.

8 Aug 2012

Surprise result in caffeine trial for Parkinson’s patients

Caffeine treatment may improve motor symptoms in patients with Parkinson’s disease, research suggests.

7 Aug 2012

Fainting appears to have strong genetic predisposition

Fainting has a strong genetic predisposition, according to new research published in the August 7, 2012, print issue of Neurology, the medical journal of the American Academy of Neurology. Fainting, also called vasovagal syncope, is a brief loss of consciousness when your body reacts to certain triggers, such as emotional distress or the sight of blood.

7 Aug 2012

Exercise partially alleviates depression in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure the results of a randomized-controlled trial show.

6 Aug 2012

Potential PD biomarkers identified for sleep behavior disorder

Concomitant olfaction abnormality and increased substantia nigra echogenicity may be preclinical manifestations of parkinsonism in patients with idiopathic rapid eye movement sleep behavior disorder, research suggests.

3 Aug 2012

Weill Cornell Medical College receives NCATS grant to fund Clinical and Translational Science Center

Weill Cornell Medical College has received $49.6 million from the National Center for Advancing Translational Sciences (NCATS), of the National Institutes of Health (NIH), to fund its Clinical and Translational Science Center (CTSC).

3 Aug 2012

Caffeine may ease movement symptoms of Parkinson's

While drinking caffeine each day does not appear to help improve sleepiness among people with Parkinson's disease, it may have a benefit in controlling movement, according to new research published in the August 1, 2012, online issue of Neurology, the medical journal of the American Academy of Neurology.

3 Aug 2012

Caffeine may help control movement in people with Parkinson's

Caffeine, which is widely consumed around the world in coffee, tea and soft drinks, may help control movement in people suffering from Parkinson's. This is the finding of a study conducted at the Research Institute of the McGill University Health Centre (RI MUHC) that was recently published in Neurology, the official journal of the American Academy of Neurology.

2 Aug 2012

Brain protein changes in PD with dementia differ from those in AD

Amyloid beta protein accumulation without neocortical tau deposition is a common pathologic feature of Parkinson’s disease with dementia, according to study findings.

1 Aug 2012

Obesity also affects sexual and urinary health in men

As a man's waistline grows, so can his experience with sexual dysfunction and frequent urination, say researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The study, published in the August issue of the British Journal of Urology International (BJUI), is the first to comprehensively show that obesity in men affects not just their hearts and metabolism, but also their sexual and urinary health.

31 Jul 2012

Alseres enters agreement with Navidea to license Altropane imaging agent

Alseres Pharmaceuticals, Inc. today announced that it has entered into an agreement with Navidea Biopharmaceuticals, Inc. to license, [123I]-E-IACFT Injection (CFT), also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson's disease and movement disorders.

31 Jul 2012